Published in

Elsevier, The Lancet Respiratory Medicine, 5(8), p. 453-460, 2020

DOI: 10.1016/s2213-2600(20)30036-9

Links

Tools

Export citation

Search in Google Scholar

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Journal article published in 2020 by Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim A. Wuyts, Susanne Stowasser, Manuel Quaresma, Rainer-Georg Goeldner, Rozsa Schlenker-Herceg, Martin Kolb, S. Abe and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO